Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Forecasts, 2019-2023: Led by Amgen, AstraZeneca, Eli Lilly & Co, Roche, and Novartis - ResearchAndMarkets.com

DUBLIN--()--The "Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

In 2018, lung cancer had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the substantial prevalence of the disease will play a vital role in the lung cancer segment to maintain its market position.

Also, this market report looks at factors such as the substantial prevalence of major cancer indications, increasing awareness campaigns, and research funding. However, the high treatment costs, high preference for alternative therapies, and patent cliff may hamper the growth of the epidermal growth factor receptor inhibitors industry over the forecast period.

Strong prevalence of major cancer indications

The prevalence of various types of cancers has increased at a significant rate in recent years, owing to increasing geriatric population and changing lifestyle. The market is witnessing the vast unmet need for novel therapies for the treatment of cancer indications. This is creating huge opportunities for vendors to conduct studies on drugs such as EGFR inhibitors for the treatment of cancer.

Thus, the substantial prevalence of major cancer indications will lead to the growth of the global EGFR inhibitors market at a CAGR of almost 9% during the forecast period.

New research areas

EGFR inhibitors are considered to be highly effective for the treatment of various types of cancer indications, which is encouraging researchers to study its use in the treatment of inflammatory and monogenic diseases. Hence, the new research areas of EGFR inhibitors are identified as a critical trend that will have a positive impact on the growth of the EGFR inhibitors market during the forecast period.

Competitive Landscape

With the presence of a few significant players, the global epidermal growth factor receptor inhibitors market is concentrated. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading epidermal growth factor receptor inhibitors manufacturers.

Also, the epidermal growth factor receptor inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all future growth opportunities.

Key Players

  • Amgen Inc.
  • AstraZeneca PLC
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG

Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY INDICATION

  • Comparison by indication
  • Lung cancer - Market size and forecast 2018-2023
  • Colorectal cancer - Market size and forecast 2018-2023
  • Breast cancer - Market size and forecast 2018-2023
  • Others - Market size and forecast 2018-2023
  • Market opportunity by indication

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • RoW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Amgen Inc.
  • AstraZeneca PLC
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG

For more information about this report visit https://www.researchandmarkets.com/r/drzq2a

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Endocrine and Metabolic Disorders Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Endocrine and Metabolic Disorders Drugs